期刊文献+

慢性肾衰竭患者血清HCY水平与其CysC、CREA的关系 被引量:4

Relationship Between Serum Homocysteine and Cystain C、Creatinine In Chronic Renal Failure Patients
下载PDF
导出
摘要 目的:探讨慢性肾衰竭患者血清同型半胱氨酸(HCY)与反映其肾功能指标的胱抑素C(CysC)、肌酐(CREA)之间的关系。方法:用循环酶法在东芝-2100全自动生化分析仪中测定40例慢性肾衰竭患者血清同型半胱氨酸(HCY),同时分别用免疫比浊法测定胱抑素C(CysC),酶法测定肌酐水平;另取100例年龄结构相仿健康体检者作为健康对照组测定其HCY、CysC、CREA水平,并进行统计学上的比较。结果:慢性肾衰竭患者血清HCY水平(22.4±10.2μmol/L)明显高于健康对照组(8.2±5.2μmol/L),两组差异有统计学意义(P<0.05)。结论:慢性肾衰竭患者血清HCY水平明显高于健康对照组,而且随着病程的进展,血清胱抑素C、肌酐水平升高,血清HCY水平也呈上升趋势,血清HCY水平可以作为监测慢性肾衰竭患者发生心血管疾病的一个重要指标。 Objective:To determin the relationship between homocysteine(HCY)and renal function(CysC、CREA).Methods:The serum HCY levels in patients with chrocic renal failure were determined with enzymatic cycling method,at the same time testing the renal function indicators(CysC、CREA).Meanwhile 100 healthy subjects with the same age structure were selected as the normal reference group for comparison.Results:Renal function indicators(CysC、CREA)in Chronic Renal Failure patients higher than those of the normal referenc group,especially the HCY level was significantly higher than the normal group(22.4±10.2μmol/L VS 8.2±5.2μmol/L,P0.05).Conclusions:Hyperhococysteine is commonly seen in Chronic Renal Failure patients and the HCY level will be increased as the renal function indictors(CysC、CREA)increasing.The HCY level can be used to predict their Cardiovascular diseases.
出处 《北方药学》 2013年第3期63-64,共2页 Journal of North Pharmacy
关键词 慢性肾衰竭 同型半胱氨酸 胱抑素C 肌酐 Chronic Renal Failure HCY CysC CREA
  • 相关文献

参考文献8

  • 1Durand P, Pmst M, Loreau U, eta|. Impaired Homocysteine metabolism and athemthmmbotic distast [J].Lab Invest,2001,81 (5) : 645-672.
  • 2杜萱,吴畅.同型(半)胱氨酸与动脉粥样硬化[J].中华心血管病杂志,2000,28(3):239-240. 被引量:72
  • 3Makw, Greene EL, Raij L. Cardiovascular risk factors in chron- ic renal failure and hemodialysis population [J]. Am J Kid Dis, 1992, 19:505-513.
  • 4Malinow MR. Homocystine and arterial occlusive disease: a mini review[J]. Clin Chem, 1994, 40:173-176.
  • 5Bostom AG, Lathrop L. Hyperhomocysteinemia in end stage renal disease: prevalence, etiology, and potential relationship to atherosclerotic ootcomes[J].Kidney Int, 1997,52:10-20.
  • 6Vasan RS, Beiser A, D Agostino RB, et al. Plasma homocys- teine and risk for congestive heart failure in adults without prior myo-cardial infarction[J] .JAMA, 2003,289 ( 10 ): 1251-1257.
  • 7郭清华,陆菊明,潘长玉,在.同型半胱氨酸与糖尿病及其微血管并发症[J].中国糖尿病杂志,2001,9(4):245-247. 被引量:29
  • 8任爱英,王凡.血清胱抑素C的临床应用及研究[J].检验医学与临床,2008,5(1):32-34. 被引量:45

二级参考文献12

  • 1闵姜勇,叶怀莲,李昌棣.胱氨酸致家兔动脉粥样硬化的实验研究[J].中国循环杂志,1994,9(6):350-353. 被引量:11
  • 2李昌棣,叶怀莲,闵姜勇,邓新,毛亚平.高胱氨酸血症与冠心病关系的临床观察及动物实验[J].中华老年医学杂志,1994,13(1):49-50. 被引量:20
  • 3[1]Anderson JK,Schmidt C,Nordin G,et al.determined by a rapid,automated particle-enhanced turbidi metric method,is a batter marker than serum creatinine for glomerular filtration rate[J].Clin Chem,1994,40(10):1921-1926.
  • 4[2]Finney H,Newman DJ,Gruber W.Initial evaluation of cystatin c measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems(BNA,BN11)[J].Clin Chem,1997,43(6):1016-1020.
  • 5[3]Randers E,Erlanden EJ.Serum Cystatin C as an endogenous marker of the renal function ; a review[J].Clin Chem Labmed,1999,37(4):389-395.
  • 6[5]Pergande M,Jung K.Sandwich enzy me immunoassay of Cystatin C in serum with commercially available antibodies[J].Chin Chem,1993,39(9):1885-1990.
  • 7[6]Randers E,Erlandsen EJ,Pederson QL.Serum Cystatin C as an endogenous parameter of renal function in patients with normal to moderately impaired kidney function[J].Chin Nephrol,2000,54(3):203-209.
  • 8Wilson A,Molecular Genetics and Metabolism,1999年,67卷,317页
  • 9高伟,中华医学杂志,1998年,78卷,821页
  • 10Chen L H,JBiol Chem,1997年,6卷,3628页

共引文献141

同被引文献43

  • 1陈文光.小剂量利尿药对23例急慢性肾功能衰竭疗效观察[J].福建医药杂志,2006,28(3):174-174. 被引量:2
  • 2范连慧,刘龙,吴晓倩,曹志强,向军.肾移植前后血浆同型半胱氨酸浓度升高与心血管病变相关[J].中华器官移植杂志,2006,27(8):506-507. 被引量:3
  • 3阮诗玮,叶彬华,吴竞,王智,陈建,庄永泽,丘余良.益肾降浊冲剂治疗慢性肾衰竭的临床观察及对血清瘦素的影响[J].中国中西医结合肾病杂志,2007,8(2):84-86. 被引量:13
  • 4Valkovsky 1, Tvrdlk J, Martfnek A, et al. Bone mineral density in patients with chronic renal failure at the start of haemodialysis therapy. Vnitr Lek, 2012,58 ( 11 ) :817 - 824.
  • 5Paul J, Dasgupta S, Ghosh MK, et al. A study of athero- sclerosis in patients with chronic renal failure with special reference to carotid artery intima media thickness. Heart Views, 2012,3(3) :91 -96.
  • 6Muiesan ML, Ambrosioni E, Costa FV, et al. Sex differ- ences in hypertension - related renal and cardiovascular dis- eases in Italy: the I -DEMAND study. J Hypertens, 2012,30 (12) :2378 - 2386.
  • 7De Giorgi A, Fabbian F, Pala M, et al. Falls and renal function: a dangerous association. G Ital Nefrol, 2012,29 (3) :293 -300.
  • 8Watorek E, Szymczak M, Boratynska M, et al. Cardiovascular risk in kidney transplant recipients receiving mammalian target of rapamycin inhibitors [ J ].Transplant Proc, 2011, 43 (8): 2967-2969.
  • 9Weir MR, Burgess ED, Cooper JE, et al. Assessment and management of hypertension in transplant patients [ J]. J Am Soe Nephrol, 2015 [ Epub ahead of print].
  • 10McCaughan JA, Courtney AE. The clinical course of kidney transplant recipients after 20 years of graft function[J]. Am J Transplant, 2015, 15 (3) : 734- 740.

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部